These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 38615803

  • 1. Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols.
    Zhang J, Khanal D, Chan HK, Banaszak Holl MM.
    Int J Pharm; 2024 May 10; 656():124116. PubMed ID: 38615803
    [Abstract] [Full Text] [Related]

  • 2. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
    Khanal D, Kim J, Zhang J, Ke WR, Holl MMB, Chan HK.
    Int J Pharm; 2023 Feb 05; 632():122563. PubMed ID: 36586629
    [Abstract] [Full Text] [Related]

  • 3. Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols.
    Khanal D, Zhang J, Ke WR, Banaszak Holl MM, Chan HK.
    Anal Chem; 2020 Jun 16; 92(12):8323-8332. PubMed ID: 32406232
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS, Kim JH, Jin SG, Kim DW, Kim JO, Yong CS, Youn YS, Oh KT, Woo JS, Choi HG.
    Pharm Dev Technol; 2018 Feb 16; 23(2):158-166. PubMed ID: 28612675
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Investigation of Electrostatic Behavior of Dry Powder-Inhaled Model Formulations.
    Jetzer MW, Morrical BD.
    J Pharm Sci; 2019 Sep 25; 108(9):2949-2963. PubMed ID: 31004652
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 25; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ, Worth Longest P, Hindle M.
    Int J Pharm; 2013 Feb 25; 443(1-2):137-45. PubMed ID: 23313343
    [Abstract] [Full Text] [Related]

  • 15. Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation.
    Muddle J, Murnane D, Parisini I, Brown M, Page C, Forbes B.
    J Pharm Sci; 2015 Nov 25; 104(11):3861-3869. PubMed ID: 26220184
    [Abstract] [Full Text] [Related]

  • 16. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO, Molokhia AM, Elsayed MM.
    Eur J Pharm Biopharm; 2015 Oct 25; 96():291-303. PubMed ID: 26275831
    [Abstract] [Full Text] [Related]

  • 17. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr 25; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 18. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.
    Louey MD, Van Oort M, Hickey AJ.
    Pharm Res; 2004 Jul 25; 21(7):1207-13. PubMed ID: 15290861
    [Abstract] [Full Text] [Related]

  • 19. Investigation into the influence of primary crystallization conditions on the mechanical properties and secondary processing behaviour of fluticasone propionate for carrier based dry powder inhaler formulations.
    Kubavat HA, Shur J, Ruecroft G, Hipkiss D, Price R.
    Pharm Res; 2012 Apr 25; 29(4):994-1006. PubMed ID: 22161310
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.